CLAREMON DAVID A has a total of 24 patent applications. Its first patent ever was published in 2004. It filed its patents most often in United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets organic fine chemistry and pharmaceuticals are PREDIX PHARMACEUTICALS HOLDING, FAES FABRICA ESPANOLA DE PRODU and SHANGHAI MEDICINE INST CHINESE.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 19 | |
#2 | WIPO (World Intellectual Property Organization) | 5 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Claremon David A | 24 |
#2 | Singh Suresh B | 22 |
#3 | Tice Colin M | 21 |
#4 | Ye Yuanjie | 21 |
#5 | Zhuang Linghang | 20 |
#6 | Leftheris Katerina | 11 |
#7 | Zhao Wei | 9 |
#8 | Xu Zhenrong | 8 |
#9 | Cacatian Salvacion | 7 |
#10 | Simpson Robert D | 3 |
Publication | Filing date | Title |
---|---|---|
US2012208804A1 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure | |
WO2010091067A2 | Derivatives of [1, 3] oxazin- 2-one useful for the treatment of metabolic diseases such as lipid disorders | |
US2011124635A1 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | |
WO2009111028A1 | Aurora kinase inhibitors | |
US2011071139A1 | Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |